Results from a recent study led researchers to advise clinicians of the potential for dystrophies that mimic age-related macular degeneration and other atrophic macular pathologies to be incorrectly diagnosed, which can impact treatment.

Researchers developed eye drop formulations 17-mer and H105A, both containing a short peptide, to administer to mice in the form of a drop on the eye’s surface.

The authors concluded that patients with autoimmune hyperthyroidism who used cannabis had a significantly increased risk for TED outcomes in the 1-year interval.

In April 2021, WCO partnered with CooperVision to introduce its myopia management standard of care, defining evidence-based standard of care comprising of mitigation, measurement, and management.

Catch up on the top stories in optometry during the week of March 17-March 21.

The 6th World Congress of Optometry will be held during Saudi Society of Optometry’s 11th Optometry Conference and Exhibition.

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

The donation given by the Frances G. Scaife Foundation will aid in the funding of 1-on-1 work and group training sessions

The Retina Institute of Illinois is led by 9 physicians who have been providing comprehensive eye care in Illinois for almost 25 years.

Patients reported that Miebo significantly reduced overall symptoms severity at the primary endpoint of change from baseline in the severity of overall dry eye symptoms at day 7.

Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.

The new mobile eye care clinic is 40 feet long and is fully equipped with an eye examination room, an eyewear dispensary stocked with frames, and a finishing lab for the production of prescription glasses.

The study evaluated 14 patients that were treated with cultivated autologous limbal epithelial cells (CALEC) and followed them for 18 months.

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

The new device from Lumenis aids in ocular surface disease treatment by combining radio frequency and dynamic muscle stimulation to improve lower lid laxity, enhance blink dynamics, and offer a non-invasive solution for dry eye management.

The survey for the report was conducted from December 13, 2024 to January 10, 2025 with a nationally representative samples of 1500 US adults and 150 eye care providers from The Vision Council’s Research Advisory Panel.